Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2023.10.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary extraskeletal osteosarcoma of rectal mesentery: a rare case and literature review.
World J Surg Oncol
January 2025
The Department of General Surgery, The Second Hospital of Jilin University, Changchun, 130041, China.
Background: Extraskeletal osteosarcoma (ESOS) is a rare kind of sarcoma with a low preoperative diagnosis and a poor prognosis. ESOS arising from abdominal mesentery is extremely rare. Increasing diagnostic methods and standardizing treatment protocols are crucial issues of ESOS.
View Article and Find Full Text PDFFrozen versus fresh embryo transfer in women with low prognosis for in vitro fertilisation treatment: pragmatic, multicentre, randomised controlled trial.
BMJ
January 2025
State Key Laboratory of Reproductive Medicine and Offspring Health, Centre for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, China
Objective: To test the hypothesis that a freeze-all strategy would increase the chance of live birth compared with fresh embryo transfer in women with low prognosis for in vitro fertilisation (IVF) treatment.
Design: Pragmatic, multicentre, randomised controlled trial.
Setting: Nine academic fertility centres in China.
Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary.
Int J Gynecol Cancer
January 2025
Memorial Sloan Kettering Cancer Center, Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA; Weill Cornell Medical College, Department of Medicine, New York, NY, USA. Electronic address:
Objective: We sought to determine the safety and efficacy of the oral progesterone antagonist onapristone in combination with anastrozole in patients with recurrent progesterone receptor-positive adult-type granulosa cell tumor of the ovary.
Methods: This was a single-institution phase II study of patients with progesterone receptor-positive adult-type granulosa cell tumor who received at least 1 prior line of chemotherapy. Patients were enrolled from November 2021 to August 2022 and tissue was evaluated for progesterone receptor status via immunohistochemistry.
A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
Anticancer Drugs
January 2025
Oncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Article Synopsis
- Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
- In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
- The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
Ascorbic acid and resveratrol improve the structural integrity of the extracellular matrix and enhance follicular survival in cultured bovine ovarian tissue.
Theriogenology
January 2025
Laboratory of Biotechnology and Physiology of Reproduction (LABIREP), Federal University of Ceará, Sobral, CE, Brazil. Electronic address:
This study aimed to investigate the changes induced by the culture system and the effect of ascorbic acid and resveratrol on collagen fibers, stromal cells, follicle growth and survival, as well as antioxidant enzyme activity in cultured bovine ovarian tissues. In experiment 1, bovine ovarian fragments were cultured in α-minimum essential medium (α-MEM) for 6 days. Before and after culturing, the fragments were fixed and processed to assess follicular morphology and diameters, stromal cell survival, collagen fibers, and glycosaminoglycans (GAGs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!